Iodixanol vs. Iomeprol to Prevent Contrast-Induced Nephropathy After Coronary Intervention (CONTRAST)
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate that Iodixanol 320 is associated with a lower
incidence of contrast-induced nephropathy (CIN) when compared with hyperosmolar contrast
medium Iomeprol 350 in patients with impaired renal function undergoing percutaneous coronary
interventions (PCI).